Trial Profile
Evaluation of plasma vascular endothelial growth factor levels after intravitreal injection of ranibizumab and aflibercept for exudative age-related macular degeneration.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Dec 2015
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary) ; Ranibizumab (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- 20 Dec 2015 New trial record